Wednesday, March 30, 2016
PeptiDream Inc., a public Tokyo-based biopharmaceutical company announced today that it has entered into a multi-target discovery and development collaboration with Tokyo-based Asahi Kasei Pharma Corp.(“Asahi Kasei Pharma”), a division of Asahi Kasei Corp. (TSE First Section: 3407). PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocylic/constrained peptides against multiple targets of interest selected by Asahi Kasei Pharma, and to optimize hit peptides into therapeutic peptides. Asahi Kasei Pharma will have the right to develop and commercialize all molecules resulting from the collaboration. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, research funding and is eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
In the past six years, PeptiDream has established funded discovery collaborations with 15 of the leading global pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, and Shionogi, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, and Lilly.
[Comment from Kiichi Kubota, President & CEO of PeptiDream Inc]
“We are very pleased to start a discovery and development collaboration with Asahi Kasei Pharma and employ our revolutionary PDPS technology to rapidly identify functional hit peptide candidates against Asahi Kasei Pharma targets, and turn those candidates into either peptide or small molecule therapeutics. Our PDPS technology is rapidly changing the way drug discovery is done, significantly speeding the process while reducing the risks associated with classic drug discovery, and this ability has been shown by the increasing number of pharma companies looking to partner with PeptiDream.”
Source : peptidream.com
